Annovis Bio Inc. to Present Findings from Phase III Buntanetap Alzheimer's Study at AAIC 2025

Reuters

2025/06/26

Annovis Bio Inc. to Present Findings from Phase III Buntanetap Alzheimer's Study at AAIC 2025

Annovis Bio, Inc. has announced its participation in the upcoming Alzheimer's Association International Conference $(AAIC)$ 2025, scheduled to take place from July 27-31 in Toronto, Canada. The company plans to present four scientific posters detailing advancements in its Alzheimer's clinical program and the pharmacokinetic characterization of its lead drug candidate, buntanetap. These presentations will cover various aspects, including the design of a Phase III study for early Alzheimer's patients, efficacy and safety results from a dual 6-month and 18-month clinical trial, and the comparative pharmacokinetic analysis of buntanetap in both its original semi-crystalline and novel crystalline forms. Additionally, the pharmacokinetic profile of buntanetap in patients with early Alzheimer's and Parkinson's diseases will be discussed. The results from these studies will be presented during the conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9484660-en) on June 26, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2546351780"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546351780\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2546351780?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-26 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546351780","market":"fut","top_or_hot":-1,"title":"Annovis Bio Inc. to Present Findings from Phase III Buntanetap Alzheimer's Study at AAIC 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Annovis Bio Inc. to Present Findings from Phase III Buntanetap Alzheimer's Study at AAIC 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ANVS\">Annovis Bio, Inc.</a> has announced its participation in the upcoming Alzheimer's Association International Conference <a href=\"https://laohu8.com/S/AAIC\">$(AAIC)$</a> 2025, scheduled to take place from July 27-31 in Toronto, Canada. The company plans to present four scientific posters detailing advancements in its Alzheimer's clinical program and the pharmacokinetic characterization of its lead drug candidate, buntanetap. These presentations will cover various aspects, including the design of a Phase III study for early Alzheimer's patients, efficacy and safety results from a dual 6-month and 18-month clinical trial, and the comparative pharmacokinetic analysis of buntanetap in both its original semi-crystalline and novel crystalline forms. Additionally, the pharmacokinetic profile of buntanetap in patients with early Alzheimer's and Parkinson's diseases will be discussed. The results from these studies will be presented during the conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9484660-en) on June 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Annovis Bio Inc. to Present Findings from Phase III Buntanetap Alzheimer's Study at AAIC 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnnovis Bio Inc. to Present Findings from Phase III Buntanetap Alzheimer's Study at AAIC 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-26 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Annovis Bio Inc. to Present Findings from Phase III Buntanetap Alzheimer's Study at AAIC 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ANVS\">Annovis Bio, Inc.</a> has announced its participation in the upcoming Alzheimer's Association International Conference <a href=\"https://laohu8.com/S/AAIC\">$(AAIC)$</a> 2025, scheduled to take place from July 27-31 in Toronto, Canada. The company plans to present four scientific posters detailing advancements in its Alzheimer's clinical program and the pharmacokinetic characterization of its lead drug candidate, buntanetap. These presentations will cover various aspects, including the design of a Phase III study for early Alzheimer's patients, efficacy and safety results from a dual 6-month and 18-month clinical trial, and the comparative pharmacokinetic analysis of buntanetap in both its original semi-crystalline and novel crystalline forms. Additionally, the pharmacokinetic profile of buntanetap in patients with early Alzheimer's and Parkinson's diseases will be discussed. The results from these studies will be presented during the conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9484660-en) on June 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDL9QyNq5:1","article_id":"2546351780","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546351780","pubTimestamp":1750939254,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Annovis Bio, Inc. has announced its participation in the upcoming Alzheimer's Association International Conference  2025, scheduled to take place from July 27-31 in Toronto, Canada. The company plans to present four scientific posters detailing advancements in its Alzheimer's clinical program and the pharmacokinetic characterization of its lead drug candidate, buntanetap. These presentations will cover various aspects, including the design of a Phase III study for early Alzheimer's patients, efficacy and safety results from a dual 6-month and 18-month clinical trial, and the comparative pharmacokinetic analysis of buntanetap in both its original semi-crystalline and novel crystalline forms. Additionally, the pharmacokinetic profile of buntanetap in patients with early Alzheimer's and Parkinson's diseases will be discussed. The results from these studies will be presented during the conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","ANVS":"Annovis Bio, Inc.","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"Annovis Bio Inc.将在AAIC 2025上展示Buntanetap阿尔茨海默病III期研究结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ANVS":0.9},"content_text":"Annovis Bio Inc. to Present Findings from Phase III Buntanetap Alzheimer's Study at AAIC 2025\n    \n\nAnnovis Bio, Inc. has announced its participation in the upcoming Alzheimer's Association International Conference $(AAIC)$ 2025, scheduled to take place from July 27-31 in Toronto, Canada. The company plans to present four scientific posters detailing advancements in its Alzheimer's clinical program and the pharmacokinetic characterization of its lead drug candidate, buntanetap. These presentations will cover various aspects, including the design of a Phase III study for early Alzheimer's patients, efficacy and safety results from a dual 6-month and 18-month clinical trial, and the comparative pharmacokinetic analysis of buntanetap in both its original semi-crystalline and novel crystalline forms. Additionally, the pharmacokinetic profile of buntanetap in patients with early Alzheimer's and Parkinson's diseases will be discussed. The results from these studies will be presented during the conference.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9484660-en) on June 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}